Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit (2019)
- Authors:
- USP affiliated authors: ZUARDI, ANTONIO WALDO - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP
- Unidade: FMRP
- DOI: 10.1016/j.neuropharm.2019.05.015
- Subjects: ESQUIZOFRENIA; CANABINOIDES; COGNIÇÃO
- Keywords: Cannabinoid drugs; Contextual fear conditioning; Schizophrenia; Vanilloid drugs
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Neuropharmacology
- ISSN: 0028-3908
- Volume/Número/Paginação/Ano: v. 155, p. 44-53, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
ALMEIDA, Valéria et al. Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit. Neuropharmacology, v. 155, p. 44-53, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2019.05.015. Acesso em: 12 fev. 2026. -
APA
Almeida, V., Levin, R., Peres, F. F., Suiama, M. A., Vendramini, A. M., Santos, C. M., et al. (2019). Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit. Neuropharmacology, 155, 44-53. doi:10.1016/j.neuropharm.2019.05.015 -
NLM
Almeida V, Levin R, Peres FF, Suiama MA, Vendramini AM, Santos CM, Silva ND da, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit [Internet]. Neuropharmacology. 2019 ; 155 44-53.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1016/j.neuropharm.2019.05.015 -
Vancouver
Almeida V, Levin R, Peres FF, Suiama MA, Vendramini AM, Santos CM, Silva ND da, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit [Internet]. Neuropharmacology. 2019 ; 155 44-53.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1016/j.neuropharm.2019.05.015 - Cannabidiol and neuroprotection: evidence from preclinical studies
- Cannabidiol displays proteomic similarities to antipsychotics in cuprizone-exposed human oligodendrocytic cell line MO3.13
- Marijuana, feijoada and the debate on drug legalization
- Cannabidiol for the treatment of psychosis in Parkinson's disease
- Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol
- Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain
- Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
- Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia
- Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system
- Cannabidiol reverses memory impairments and activates components of the Akt/GSK3β pathway in an experimental model of estrogen depletion
Informações sobre o DOI: 10.1016/j.neuropharm.2019.05.015 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
